Panobinostat was also evaluated in combination with the mTOR inhibitor everolimus in 3 clinical trials in a cohort of B-, T-NHL and Hodgkin lymphoma (HL) patients (NCT00918333, NCT00967044, NCT00978432), in which the best response was an ORR of 33%, and OS and PFS of 35 and 4.2 months, respectively. The gene discussed is MTOR; the disease is Hodgkins lymphoma.